Bausch & Lomb
Executive Summary
FDA issues Oct. 1 warning letter regarding manufacturing problems for neomycin/polymyxin B/dexamethasone ophthalmic suspension, which is used for vernal conjunctivitis and keratitis. FDA cited dexamethasone precipitate that collects in the tip of the product container tip as the major problem to be addressed by the company